Welcome to our dedicated page for Alto Neuroscienc SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical biotech filing can feel like decoding neuroscience itself. Alto Neuroscience’s 10-K dives into biomarker validation for ALTO-100, ALTO-202, and other pipeline assets, while its 8-Ks track every trial milestone. If you have ever searched for Alto Neuroscience SEC filings explained simply, this page is made for you.
Stock Titan’s AI distills the data that matters—cash runway, trial endpoints, and risk factors—so understanding Alto Neuroscience SEC documents with AI becomes routine. Real-time alerts surface Alto Neuroscience Form 4 insider transactions real-time, letting you spot confidence shifts before headlines hit. Need the latest numbers? Our platform pairs every Alto Neuroscience quarterly earnings report 10-Q filing with side-by-side benchmarks, turning dense tables into clear trend lines.
- Alto Neuroscience insider trading Form 4 transactions at a glance—track each executive move.
- Instant Alto Neuroscience 8-K material events explained so trial updates never slip past you.
- Concise Alto Neuroscience annual report 10-K simplified summaries pinpointing R&D spend and biomarker strategy.
- Actionable Alto Neuroscience earnings report filing analysis to compare quarter-over-quarter progress.
- Transparent Alto Neuroscience proxy statement executive compensation details to evaluate incentives.
- Granular view of Alto Neuroscience executive stock transactions Form 4 for pattern recognition.
Whether you’re modeling cash burn or gauging insider confidence, our AI-powered summaries, real-time EDGAR feeds, and expert context turn Alto Neuroscience disclosures into decision-ready intelligence. No more scanning hundreds of pages—just the insights you need, when you need them.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 1,624,000 shares of Alto Neuroscience (ANRO), representing 6.0% of the outstanding common stock based on 27,072,129 shares outstanding. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Mr. Boyd, as managing member, report shared voting and shared dispositive power over these shares and no sole voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of influencing control. The Master Fund is identified as the direct holder and retains the right to proceeds or dividends from the securities.
Alto Neuroscience director Ramiro Sanchez received equity awards disclosed on Form 4 dated 08/12/2025. The report shows two stock option grants exercisable at $3.18 per share covering 30,574 and 3,928 underlying shares. The larger option vests in 36 equal monthly installments beginning September 12, 2025; portions of the smaller option vest on September 30, 2025 (1,383 shares) and December 31, 2025 (2,545 shares). The smaller option was issued in lieu of $8,682.07 in retainer fees and carried an exercise price disclosure of $2.21 for that grant. Both grants are reported as direct beneficial ownership.
Alto Neuroscience (ANRO) reported unaudited results for the quarter ended June 30, 2025 showing continued clinical progress alongside ongoing operating losses. Cash and cash equivalents were $147.6 million and restricted cash $0.5 million at June 30, 2025, down from $168.2 million at year-end. The company recorded a net loss of $17.7 million for the three months and $32.9 million for the six months ended June 30, 2025, with R&D expense of $23.1 million and G&A of $11.3 million for the six-month period. Accumulated deficit totaled $171.3 million. Financing activity included proceeds from a $20.0 million draw under an amended term loan and an increase in term loan principal and related debt issuance costs; term loan maturity extended to January 1, 2029 with a weighted-average interest rate of 12.96% recorded in 2025. The company has a $2.0 million Convertible Grant Agreement with Wellcome, classified at fair value. Clinical programs advanced: topline data expected mid-2026 for ALTO-300 and in H2 2026 for ALTO-100; acquisition of ALTO-207 and ALTO-208 was completed in May 2025. Management notes continued reliance on external financing to fund operations.
Alto Neuroscience reported results for the fiscal quarter ended June 30, 2025; a press release is furnished as Exhibit 99.1 to this report.
The company’s Board increased from five to six members and appointed Ramiro (Raymond) Sanchez, M.D., age 64, as an independent Class II director with a term expiring at the 2026 Annual Meeting. Dr. Sanchez brings more than 20 years of life sciences experience, including roles as Chief Medical Officer and senior global clinical development positions, and currently serves as a Senior Advisor at Bain Capital Life Sciences.
Under the Non-Employee Director Compensation Policy Dr. Sanchez will receive an initial option grant to purchase 30,574 shares vesting in equal monthly installments over three years, an annual option grant of 15,287 shares, a $40,000 annual cash retainer plus a $5,000 annual NCGC retainer, and standard indemnification. The Board also rebalanced director classes and updated committee memberships.
FAQ
What is the current stock price of Alto Neuroscienc (ANRO)?
What is the market cap of Alto Neuroscienc (ANRO)?
